#ASCO21: AstraZeneca's PD-1 Imfinzi tacks on 5-year survival data in NSCLC, which it's calling 'unprecedented'

Amid a sea of competitors in PD-1, AstraZeneca has looked to outrun the big dogs in Merck and Bristol Myers Squibb with its Imfinzi. One way to differentiate? Long-term effect — and now AstraZeneca has five-year data in NSCLC it thinks can set its drug apart.